bms-3

BMS-3 is a potent LIMK inhibitor with IC50 values of 5 nM and 6 nM for LIMK1 and LIMK2, respectively.

BMS-363131 (BMS363131) is a potent and selective trypsin inhibitor with an IC50 value of <1.7 nM.

BMS-394136 (BMS 394136) is a KV1.5 antagonist for the treatment of cardiovascular diseases such as arrhythmias and atrial fibrillation.

BMS-345541 (IKK Inhibitor III) is a highly selective inhibitor of the catalytic subunits of IKK-2 and IKK-1 with IC50 of 0.3 μM and 4 μM, respectively.

BMS-309403 sodium is a potent, orally active, selective inhibitor of adipocyte fatty acid binding protein (FABP4, aP2), with inhibitory constants (Ki) of <2 nM for FABP4, 250 nM for FABP3, and 350 nM for FABP5. It competitively binds to the fatty-acid-binding pocket of the protein, impeding the attachment of endogenous fatty acids. This compound enhances endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells, underlining its potential therapeutic benefits [1] [2] [3].

BMS-37 is a PD-1/PD-L1 immune checkpoint inhibitor exhibiting IC50 values ranging from 18 to 200 nM against the PD-L1/PD-1 complex, while displaying nonspecific cytotoxicity toward modified Jurkat T cells with EC50 values between 3 and 6 μM, and it is widely used to investigate PD-L1–induced T-cell exhaustion mechanisms or as a PD-L1 ligand scaffold for the rational design and synthesis of PROTAC molecules in immuno-oncology research.

BMS-341400 mesylate (Compound 6) is an orally active selective phosphodiesterase 5 (PDE5) inhibitor with an IC50 value of 0.3 nM and is useful in the study of erectile dysfunction.

BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor (IC50: 0.13 uM, human recombinant ACL).

BMS-317180 is a potent, novel, orally effective growth hormone secretagogue (GHS) that shows an excellent safety profile in preclinical studies. The compound was advanced into clinical development.

BMS-344577, a lactam derivative based on arylguanidine, is a potent oral active FXA inhibitor with excellent susceptibility in vitro, good pharmacokinetics, and pharmacodynamics in animal models.

BMS-346567 is a potent and selective dual angiotensin II and endothelin receptor antagonist.

BMS-347070 is a COX-2 inhibitor.

BMS-354326 is a bio-active chemical.

BMS-358233 is an effective LCK inhibitor with excellent cell activity against T cell proliferation.

BMS309403 is a potent and selective inhibitor of adipocyte fatty acid binding protein aFABP. It improves endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells. It interacts with the fatty acid binding pocket inside the protein and competitively inhibits the binding of endogenous fatty acids.

BMS-378806 (BMS-806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.

BMS-351 is a potent and selective, nonsteroidal CYP17A1 lyase inhibitor with robust selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 emerges as an outstanding preclinical candidate to treat CRPC and is likely to minimize the side effects of current therapies due to its exceptional selectivity. BMS-351 is potentially useful for the Treatment of Prostate Cancer.

BMS-332 is a dual inhibitor of the lipid kinases DGKα and DGKζ, demonstrating half-maximal inhibitory concentrations (IC50) of 0.005 μM for DGKα and 0.001 μM for DGKζ [1].

BMS-345541 hydrochloride is a selective IKK inhibitor, targeting IKK2 and IKK1 with IC50 values of 0.3 μM and 4 μM, respectively.

BMS-337197 is an IMPDH inhibitor.

Dasatinib (BMS-354825) is an orally active, ATP-competitive tyrosine kinase inhibitor that targets Src and Bcr-Abl (Ki=16/30 pM), with antitumor activity, used in the treatment of leukemia and lymphoma.

Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.

Dasatinib hydrochloride (BMS-354825 HCl) (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib hydrochloride hydrochloride also induces Apoptosis and Autophagy.

Dasatinib D8 is deuterium-labeled dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.